300 Results
Sort By:
Published on December 19, 2019
A new study found that the Karius Test, which uses microbial cell-free DNA (mcfDNA-seq), can predict bloodstream infections in leukemia patients up to three days before the onset of symptoms. This is the first evidence the test can predict infections. Investigators at St. Jude Children’s Research Hospital used the test…
Published on April 18, 2019
Statistics can be a great tool for analyzing datasets and it can also be a sobering means to provide a stark reality. For instance, recent data suggests that approximately every three minutes one person in the United States is diagnosed with some form of blood cancer. While this statistic shows…
Published on October 30, 2018
Sponsor: Horizon Discovery Gene editing and gene modulation technology company Horizon Discovery Group has launched a new Myeloid DNA Reference Standard. This large cell-line derived myeloid cancer reference standard enables faster, more reliable, and more cost-effective assay validation, to support the market in bringing routine testing into practice. The cell…
Published on September 14, 2018
A new study finds that children with B-cell precursor acute lymphoblastic leukemia (ALL) have an immune profile at birth that differs from matched controls. Although the cause of ALL remains unknown, this finding lends support to the hypothesis that a dysregulated immune function in combination with certain postnatal environmental exposures…
Published on February 6, 2018
Swiss artificial intelligence health company Sophia Genetics announced the launch of what it calls the world’s first capture-based myeloid clinical solution to receive the CE-IVD mark. The Myeloid Solution comprehensively covers genes associated with hematological disorders to provides clinicians with rapid and precisely analyzes their patients’ DNA. The test includes…
Published on November 21, 2017
The Leukemia & Lymphoma Society (LLS) has committed an additional $46 million toward 87 new blood cancer research projects at institutions worldwide. The new funding will increase to 254 the number of grants in LLS's total active research portfolio—which according to the society represents more investment in blood cancer research…
Published on November 1, 2016
A team of investigators led by scientists at St. Jude Children's Research Hospital and the Washington University Pediatric Cancer Genome Project (PCGP) has published a comprehensive map of the genomic landscape for the form of acute myeloid leukemia (AML) called core-binding factor acute myeloid leukemia (CBF-AML). This new work reveals…
Published on August 29, 2016
Scientists at the University of California San Diego School of Medicine and Moores Cancer Center have published new evidence for RNA-based biomarkers that can distinguish between normal, aging hematopoietic stem cells and leukemic stem cells associated with secondary acute myeloid leukemia (sAML). The new study—“RNA Splicing Modulation Selectively Impairs Leukemia…
Published on April 26, 2016
A new research study, led by scientists at St. Jude Children's Research Hospital, has identified a rare genetic variation associated with a dramatically increased risk of severe acute pancreatitis in acute lymphoblastic leukemia (ALL) patients treated with the chemotherapy agent asparaginase. Asparaginase is an essential agent used to treat ALL…
Published on October 15, 2015
Researchers from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard have harnessed the power of next-generation sequencing to analyze a large collection of leukemia tissue samples. Using whole exome sequencing (WES), the investigators screened genetic material from more than 500 samples of chronic lymphocytic leukemia (CLL)…
Published on August 26, 2015
While the incidence of acute myeloid leukemia (AML) is still relatively rare, accounting for approximately 1% of cancer deaths in the U.S., rates of occurrence are expected to rise as the largest portion of the population continues to age. Moreover, there remains a significant level of disparity in clinical outcomes,…
Published on April 24, 2024
Researchers at the University of California, San Francisco (UCSF) have begun enrollment for a clinical trial that uses a new, powerful version of CAR T as a potential therapy for glioblastoma, the most common and deadly adult brain cancer. The clinical trial is funded by an $11 million grant to…
Published on April 24, 2024
A Phase I trial led by the Baylor College of Medicine shows an autologous chimeric antigen receptor (CAR) T-cell therapy for treatment of advanced HER2-specific sarcoma was beneficial in 50% of patients in the trial. Lower-level cytokine release syndrome was fairly common in the study, but only two individuals had…
Published on April 10, 2024
For the past ten years or so, APOBEC3 cytidine deaminases (APOBEC) enzymes have emerged as important cancer targets in a number of solid tumor types. Their mutational rate is higher in cancer cells than in normal cells and when they are expressed in cancers, those cancers have a worse prognosis.…
Published on April 4, 2024
Patients with slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment who stopped specialist visits showed comparable three-year survival rates compared with those who continued to receive specialized follow up. The research from a team of Danish investigators, published today in Blood Advances,…